In-house peptide synthesis reduces costs and shortens turnaround times | PurePep Blog

Ab Biotechnology’s decision to transition from outsourcing peptide synthesis to producing in-house marks a powerful example of how reliable and innovative technology can expand business. By adopting the flexible PurePep^® Chorus synthesizer from Gyros Protein Technologies, they enhanced quality control, reduced costs, and accelerated project timelines—transforming their operations. 

This pivot highlights the tangible benefits of in-house peptide synthesis, particularly for organizations focused on production according to GMP principles. Ab Biotechnology’s success provides a roadmap for companies looking to optimize their peptide synthesis efforts and improve operational efficiency. 

The Problem: Bottlenecks in Outsourcing 

Renowned for delivering high-purity peptides to biotech companies and startups, Ab Biotechnology faced challenges with its outsourcing model due to increasing client demand. 

Key pain points: 

Quality concerns: Ensuring rigorous demand for GMP-compliant starting materials was challenging when relying on third-party suppliers.

Cost and time pressure: Outsourcing led to inflated production costs and prolonged timelines, impacting their ability to meet the rapid demands of biotech startups. 

Limited control: The lack of in-house production limited their ability to oversee critical processes and respond flexibly to client needs.

To overcome these problems and meet the growing demand, Ab Biotechnology needed a more efficient and reliable solution. 

The Solution: Bringing peptide synthesis in-house

Ab Biotechnology partnered with Gyros Protein Technologies to implement the PurePep^® Chorus synthesizer, a reliable and flexible platform designed for precise, scalable, and GMP-compliant peptide synthesis. 

Key features of the PurePep Chorus:

• Reliability: Delivers consistent performance with minimal cross-contamination and industry-best purity.
• Flexibility: Adapts to diverse research needs with variable chemistries and advanced features.
• Compliance: User-friendly software with CFR Part 11 compliance for regulated environments.

To support the new synthesizer technology, Ab Biotechnology invested in a dedicated peptide synthesis lab. The facility was purpose-built with optimized electrical systems, nitrogen supply, and workflow design to ensure seamless operation of the PurePep^® Chorus platform. Gyros Protein Technologies provided extensive support, including off-site trials, technical troubleshooting, and comprehensive training, ensuring a smooth transition to in-house production. 

Gyros Protein Technologies facilitated off-site trials, offered tailored solutions for technical hurdles, and provided exceptional training that made the integration process smooth and successful.

Tam Cameron, CEO of Ab Biotechnology

The Result: Improved capacity and quality 

Ab Biotechnology's strategic decision to bring peptide synthesis in-house delivered significant improvements. 

Business growth and new opportunities

• New products: The development of a catalog of unique peptides, tackling complex challenges like solubility and purification.
• More capabilities: The increased capacity enabled expansion of services to new and existing clients, further strengthening the market position.
• Team expansion: With increased customer demand, Ab Biotechnology expanded its peptide synthesis team.

Lessons learned

Internalizing peptide production with the PurePep Chorus enabled a transformation of the business. By addressing key challenges—cost, efficiency, and quality—Ab Biotechnology achieved measurable improvements that redefined its operations. 

This success underscores the importance of: 

1. Reliability: Proven synthesizers like the PurePep Chorus ensure uninterrupted operations, reducing downtime and shortening timelines
2. Flexibility: The PurePep Chorus supports diverse research and production needs, adapting to evolving scales and enabling complex chemistries
3. Compliance: CFR Part 11 compliant software, as well as a proven track record of the synthesizer in regulated environments, ensures seamless transition to new market segments
4. Partnering with experts: Working with Gyros Protein Technologies gives access to specialist knowledge and responsive support for fast technology adoption

With a 50% reduction in timelines and a two-year ROI, Ab Biotechnology has showcased the transformative potential of automated peptide synthesis. For organizations exploring similar transitions, their journey serves as an inspiring case study on the strategic value of innovation. 

Download the full Case Study here 

Curious to learn more about peptide therapeutics and automated peptide synthesis? 

Don't hesitate to get in touch with our team to schedule a consultation. 

You want to learn more about Ab Biotechnology’s services?

Get in contact with Ab Biotechnology on www.abbiotechnology.com